» Articles » PMID: 20712392

Cost Sharing, Adherence, and Health Outcomes in Patients with Diabetes

Overview
Journal Am J Manag Care
Specialty Health Services
Date 2010 Aug 18
PMID 20712392
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess the relationship between cost sharing and adherence to antidiabetic medications in patients with type 2 diabetes and to examine the relationship between medication adherence and outcomes, including complication rates, medical service utilization, and workplace productivity measures.

Study Design: A retrospective, cross-sectional study analyzing the healthcare experience of patients with type 2 diabetes on oral antidiabetic medication (OAD) with or without insulin (n = 96,734) and patients on OAD only (n = 55,356) with employer-sponsored insurance in the 2003-2006 MarketScan Database.

Methods: Using a 2-stage residual inclusion model, the first stage estimated the effects of cost sharing on adherence to antidiabetic medications in an 18-month time frame (January 2003 through June 2004). Adherence was determined from the percentage of days covered. The second stage estimated the effects of adherence on complication rates (eg, retinopathy, neuropathy, peripheral vascular disease), medical service utilization rates, and measures of productivity (absence days and short-term disability days) in the subsequent 2 years (July 2004 through June 2006).

Results: A $10 increase in the patient cost-sharing index resulted in a 5.4% reduction in adherence to antidiabetic medications for patients on OAD only and a 6.2% reduction in adherence for patients on OAD with or without insulin. Adherence was associated with lower rates of complications (eg, amputation/ulcers, retinopathy) and also was associated with fewer emergency department visits and short-term disability days.

Conclusions: Medical plans, employers, and policy makers should consider implementing interventions targeted to improve antidiabetic medication adherence, which may translate to better outcomes.

Citing Articles

Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective.

Harris S, Cimino S, Nguyen Y, Szafranski K, Poon Y Diabetes Ther. 2024; 16(2):169-186.

PMID: 39688778 PMC: 11794756. DOI: 10.1007/s13300-024-01677-5.


Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective.

Torre E, Di Matteo S, Bruno G, Martinotti C, Bottaro L, Colombo G Clinicoecon Outcomes Res. 2024; 16:799-811.

PMID: 39525695 PMC: 11550686. DOI: 10.2147/CEOR.S475461.


Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.

Horii T, Masudo C, Takayanagi Y, Oikawa Y, Shimada A, Mihara K J Diabetes Investig. 2024; 15(11):1578-1584.

PMID: 39243175 PMC: 11527826. DOI: 10.1111/jdi.14265.


Beneficial Effect of Remote Glucose Monitoring and Computerized Insulin Dose Adjustment Algorithms Independent of Insulin Dose Increases in Sizeable Minorities of Patients.

Davidson M, Davidson S, Duran P Clin Diabetes. 2024; 42(3):364-370.

PMID: 39015160 PMC: 11247028. DOI: 10.2337/cd23-0066.


A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone.

Shaikh S, Vaidya V, Gupta A, Kulkarni R, Joshi A, Kulkarni M Cureus. 2024; 16(5):e59850.

PMID: 38854289 PMC: 11157142. DOI: 10.7759/cureus.59850.